Journal
JOURNAL OF ALZHEIMERS DISEASE
Volume 55, Issue 1, Pages 67-72Publisher
IOS PRESS
DOI: 10.3233/JAD-160574
Keywords
Alzheimer's disease; amyloid-beta; DJ-1; Parkinson's disease
Categories
Funding
- JSPS KAKENHI
- Smoking Research Foundation (SRF)
- Ritsumeikan University in Japan
- Program for Promotion of Fundamental Studies in Health Science of the National Institute of Biomedical Innovation (NIBIO) in Japan
- Grants-in-Aid for Scientific Research [15K16321, 16K08286, 16H05279] Funding Source: KAKEN
Ask authors/readers for more resources
Previously, DJ-1 modulator UCP0054278/comp-B was identified by virtual screening, where comp-B interacts with DJ-1 to produce antioxidant and neuroprotective responses in Parkinson's disease models. However, the effect of comp-B in an in vivo Alzheimer's disease (AD) model is yet undetermined. Thus, we examined the effect of comp-B on spatial learning, memory, and amyloid-beta (A beta) clearance in a transgenic mouse model of AD. We found that comp-B resolved the cognitive deficits, reduced insoluble A beta(42) levels, and prevented the degeneration of synaptic functions, thereby suggesting that comp-B may become a major compound for AD treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available